Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Controlled, Clinical Food Study to Evaluate the Effect of KB174 Compared to an Easily Digestible Polysaccharide on Function and Structure of the Gut Microbiome in Subjects With Well-compensated Cirrhosis

Next Previous
Trial Profile

A Randomized, Double-blind, Controlled, Clinical Food Study to Evaluate the Effect of KB174 Compared to an Easily Digestible Polysaccharide on Function and Structure of the Gut Microbiome in Subjects With Well-compensated Cirrhosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KB 174 (Primary) ; Maltodextrin
  • Indications Hyperammonaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kaleido Biosciences

Most Recent Events

  • 07 Oct 2020 According to a Kaleido Biosciences media release, data from this trial will be featured during The Liver Meeting 2020, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in a virtual format.
  • 29 Aug 2020 Results presented at The International Liver Congress 2020
  • 27 Aug 2020 According to a Kaleido Biosciences media release, data from this study will be featured during The Digital International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver (EASL).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top